Avalyn Pharma Inc. Common Stock (AVLN) vs Bicara Therapeutics Inc. Common Stock (BCAX)

A side-by-side comparison of Avalyn Pharma Inc. Common Stock and Bicara Therapeutics Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Avalyn Pharma Inc. Common Stock logo
AVLN
Avalyn Pharma Inc. Common Stock
$1.14B
$25.64HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
Bicara Therapeutics Inc. Common Stock logo
BCAX
Bicara Therapeutics Inc. Common Stock
$1.09B
$16.63HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT

Total return — AVLN vs BCAX

growth of $100 · dividends reinvested · last 1y
AVLN -8.3% (-8.3%/yr)BCAX -19.9% (-19.9%/yr)AVLN compounded faster over this window
80100120140Start $100$92$80
AVLN BCAX

AVLN vs BCAX: by the numbers

  • •AVLN is the larger company ($1.14B vs $1.09B market cap).

Metrics side by side

Valuation

MetricAVLNBCAX
P/B ratio2.852.33

Profitability

MetricAVLNBCAX
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROEN/A-39.54%
ROIC-67.73%-42.98%

Go deeper

Full AVLN analysisFull BCAX analysisInteractive comparison tool

Dig into the metrics

Avalyn Pharma Inc. Common Stock ROEBicara Therapeutics Inc. Common Stock ROEAvalyn Pharma Inc. Common Stock operating marginBicara Therapeutics Inc. Common Stock operating marginAvalyn Pharma Inc. Common Stock revenue growthBicara Therapeutics Inc. Common Stock revenue growthAvalyn Pharma Inc. Common Stock free cash flowBicara Therapeutics Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.